Inicio
Explorar
nav.journalClub
Tendencias
Más
Synapse
⌘+K
Synapse
Idioma
Español
Español
September 16, 2025
Open Access
Ver artículo completo
Table 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit
CX
Camila Bragança Xavier
The University of Texas MD Anderson Cancer Center
CA
Clark R. Andersen
The University of Texas MD Anderson Cancer Center
JL
JoAnn Lim
The University of Texas MD Anderson Cancer Center
Ver todo
Puntos clave
Survival outcomes are affected by drug interactions in patients with solid tumors undergoing immunotherapy.
The analysis highlights variables influencing treatment efficacy, emphasizing the need for tailored approaches.
Assessment was performed using a phase I unit focusing on interactions between various therapeutic agents.
Understanding these interactions may enhance patient management and improve treatment strategies in solid tumors.
Resumen
Summary of variables related to survival.
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Preguntar a la IA
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Ver artículo completo
Cite This Study
Copy
Xavier et al. (Mon,) studied this question.
synapsesocial.com/papers/68d4508931b076d99fa586b5
https://doi.org/https://doi.org/10.1158/2767-9764.30126777
Table 3 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit | Synapse